title: [Multipurpose psyllium monotherapy in patients with diverticular disease].
abstract: The purpose of the research was the study of the prebiotic and hypolipidemic effects of 12-week treatment by psillium of patients with uncomplicated diverticular disease and hyperlipidemia. It has been established that the examined medicine has not any by-effects, normalizes intestinal motility and lowers a pain syndrome and flatulence. Prebiotic effect has proved by higher concentration of short-chain fatty acids in faeces and reduction of anaerobic index. Psillium certainly reduces levels of hyperlipidemia and could be recommended as hypolipidemic remedy for monotherapy as long as base datum of cholesterol is less than 6,4 mmol/l.
authors: I A
authors: IA
authors: Komissarenko
authors: S V
authors: SV
authors: Levchenko
authors: S Iu
authors: SIu
authors: Sil'vestrova
authors: T A
authors: TA
authors: Kosacheva
authors: K K
authors: KK
authors: Noskova
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002400:Cathartics / Q000008:administration & dosage / Q000627:therapeutic use*; D043963:Diverticulosis, Colonic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005232:Fatty Acids, Volatile / Q000032:analysis; D005243:Feces / Q000737:chemistry; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011620:Psyllium / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002400:Cathartics; D005232:Fatty Acids, Volatile; D000960:Hypolipidemic Agents; D008055:Lipids; D011620:Psyllium